Agena Bioscience

Executive Summary

Agena Bioscience, headquartered in San Diego since 2011, empowers molecular laboratories worldwide with scalable, targeted genomic analysis. Its flexible MassARRAY platform and extensive assay portfolio enable high-throughput, cost-effective genetic testing for pharmacogenetics, hereditary diseases, and liquid biopsy. The company serves both research and diagnostic markets, positioning itself as a key enabler of precision medicine. With a focus on targeted sequencing and multiplexing, Agena addresses the growing demand for accessible genomic data in clinical and research settings. However, as a private company, its financials and stage remain undisclosed, limiting visibility into growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026Launch of new liquid biopsy assay for early cancer detection75% success
• H2 2026Strategic partnership with major pharmaceutical company for companion diagnostics70% success
• Q4 2026CE-IVDR certification for expanded European market access80% success